A federal vaccine panel said Tuesday the benefits of the Pfizer-BioNTech COVID-19 vaccine for children ages 5-11 years outweigh the potential risks, although some expressed hesitation in recommending it for all children in this age group.
Members of the Food and Drug Administration’s (FDA’s) Vaccines and Related Biological Products Advisory Committee said they want to protect children from COVID-related infections, hospitalizations and deaths as well as disruptions to their education. However, the risk of myocarditis, though rare, gave some pause.
Source: American Academy of Pediatrics
Number of COVID-19 Omicron variant cases in Europe as of November 29, 2021, by country
In late-November 2021, the Omicron variant of SARS-CoV-2 (the virus which causes COVID-19) was designated as a variant of concern by the World Health Organization due to fears about a higher transmissibility from the variant and a possible decrease in the effectiveness of vaccines against it.